Patient Advocates in Research: New Possibilities, New Problems by Dresser, Rebecca
Washington University Journal of Law & Policy 
Volume 11 Promoting Justice Through Interdisciplinary Teaching, Practice, and Scholarship 
January 2003 
Patient Advocates in Research: New Possibilities, New Problems 
Rebecca Dresser 
Washington University School of Law 
Follow this and additional works at: https://openscholarship.wustl.edu/law_journal_law_policy 
 Part of the Health Law and Policy Commons 
Recommended Citation 
Rebecca Dresser, Patient Advocates in Research: New Possibilities, New Problems, 11 WASH. U. J. L. & 
POL’Y 237 (2003), 
https://openscholarship.wustl.edu/law_journal_law_policy/vol11/iss1/9 
This Dedication is brought to you for free and open access by the Law School at Washington University Open 
Scholarship. It has been accepted for inclusion in Washington University Journal of Law & Policy by an authorized 
administrator of Washington University Open Scholarship. For more information, please contact 
digital@wumail.wustl.edu. 
 
 
 
 
 
 
Patient Advocates in Research: New Possibilities, 
New Problems 
Rebecca Dresser∗ 
I have spent my professional life working in medical schools and 
law schools—always feeling that I do not quite fit in at either place, 
but exhilarated by the differences and by the challenges of 
translation. Focusing one’s teaching and scholarship on bioethics and 
law is wonderful. The topics grip most people because they concern 
fundamental moral and personal matters, such as death and dying, 
reproductive choice, and the pursuit of scientific knowledge. Some of 
these topics are human embryonic stem cell research, decisions about 
end-of-life treatment, and access to health care. The focus of this 
Article, patient advocacy in research, has a somewhat lower profile. 
This topic is particularly important, however, because it raises issues 
that touch on many of the topics that keep bioethics in the public eye. 
During the 1980s and 1990s, patient advocates became key 
figures in decisions carrying important ethical and policy 
implications. Unfortunately, the bioethics community did not pay 
much attention to this phenomenon. Bioethics scholars should have 
paid attention, however, not only because of the advocates’ growing 
influence, but also because bioethics is predicated on the premise that 
public and patient values matter—that physicians, scientists, and 
government officials should not completely control how medicine 
and research are practiced. Patient advocates brought to medicine and 
research the public participation that the bioethics community had 
been endorsing. As a result, I decided to take a close look at what 
advocates were doing in research and to consider whether this 
development was good, bad, or mixed. I eventually wrote a book 
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about research advocacy upon which portions of this Article are 
based.1 
The first part of this Article supplies background information on 
advocacy activities. The second part describes five themes in research 
advocacy. In the third part, I propose three ethical principles to guide 
research advocacy. I close by discussing three future challenges for 
patient advocates. 
I. PATIENT ADVOCATES IN RESEARCH 
During the 1980s, HIV/AIDS activists became major figures in 
biomedical research. They helped convince officials at the Food and 
Drug Administration (FDA) to speed up the drug approval process 
and to allow patients to use investigational drugs before the full 
testing process was completed. Scientists began to recognize the 
valuable contributions that certain HIV/AIDS activists could make to 
the decision-making process regarding research design, funding, and 
policy.  
Eventually, other patient advocacy organizations became more 
active in the research arena. Advocates persuaded government 
officials to ease the rules governing patients’ access to investigational 
medications for a variety of serious, life-threatening conditions. 
Advocates joined scientific teams in designing, conducting, and 
interpreting the results of research projects. They served on review 
panels deciding which research proposals should be funded. 
Advocates also lobbied Congress for more government funding to 
support research that could help the advocates’ constituents. 
Additionally, they participated in research ethics reviews at the 
institutional, state, and federal levels. Their activities raised the 
public profile of biomedical research, which, in turn, contributed to a 
media explosion of health research stories. 
Advocates’ quest for influence changed the politics of biomedical 
research. In a variety of settings, advocates now challenge 
government officials and scientists to explain and defend their 
 
 1. REBECCA DRESSER, WHEN SCIENCE OFFERS SALVATION: PATIENT ADVOCACY AND 
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priorities for research funding and plans for conducting specific 
studies. In response, scientists worry that advocates focus too much 
on cures and treatments without recognizing that basic research is the 
foundation for clinical applications. Researchers also fear that good 
science is threatened by factors such as the willingness of seriously ill 
people to “try anything” after conventional therapies have failed. 
Further, government officials are unsettled by the apparent 
competition among patient advocacy organizations seeking federal 
research dollars.  
These concerns partly reflect the reluctance of both scientists and 
government officials to share their power in research decision-
making. Yet the concerns are also related to ethical and policy issues 
raised by patient advocacy. On one hand, patient advocacy could 
contribute to a biomedical research enterprise that is more attuned to 
the needs and preferences of the people that the enterprise is designed 
to assist. Advocates could keep scientists’ personal and professional 
aims from having too much control over the research agenda. Patient 
advocacy could also lead to more effective communication of 
potential study risks and benefits to prospective volunteers. In 
addition, advocacy offers fresh opportunities for communication 
between scientists and the public. Increased communication would 
not only give scientists a valuable insight into the human side of the 
problems they study, but it would also provide the public with a more 
realistic picture of how research works and what it can achieve.  
On the other hand, positive results are not guaranteed. Genuine 
communication between scientists and the public is rare. Such 
communication requires mutual willingness to learn and value the 
other’s knowledge. Some in the research establishment challenge the 
use of scarce resources to increase public involvement. Others try to 
increase involvement cheaply, mostly for public relations purposes. 
Advocates in policy settings must depart from their usual single-
interest lobbying, but their appropriate role in policy activities is 
unclear. In sum, there are both bright and dark sides to patient 
advocacy in research.  
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II. ADVOCACY THEMES  
Five general themes are evident in advocacy activities. First, 
advocates tend to stress the positive dimensions of biomedical 
research. In much advocacy communication, there is a failure to 
clearly distinguish between partially tested experimental 
interventions and proven medical care. Consistent with this approach, 
advocates often portray study participation as the way to obtain 
cutting-edge therapy.  
This failure to draw a clear line between investigational 
interventions and established clinical care affects the perceptions of 
patients and of the general public. It can promote the therapeutic 
misconception—a phenomenon that occurs when people do not 
understand the aims and methodological requirements of biomedical 
research.2 The primary purpose of research is to gain knowledge that 
will improve care for future patients, not to deliver treatment tailored 
for an individual patient. When research and treatment are confused, 
patients may enroll in research studies without a good understanding 
of the trade-offs involved. Such patients may have an unrealistic hope 
for personal benefit without recognizing the risks and uncertainties 
accompanying their participation in the studies.3 
Patient advocates may also promote the therapeutic misconception 
at a broader level. For example, patient advocates often suggest that 
research can end the suffering and deprivation inflicted by illness. 
The general message is that with more funding for research, cures are 
destined to emerge. Although this feel-good message may lift the 
spirits of people coping with disease and injury, and aid with 
fundraising, it may also promote public misunderstanding of the 
research process. There is no question that research can lead to health 
care improvements. Almost always, however, it takes many years and 
many false starts before effective practical applications become 
available. But advocates too often downplay this part of research; 
instead, they equate support for research with support for imminent 
 
 2. The term “therapeutic misconception” was coined by Paul Appelbaum, Loren Roth, 
and Charles Lidz in 1982. See Paul S. Appelbaum et al., The Therapeutic Misconception: 
Informed Consent in Psychiatric Research, 5 INT’L J. L. & PSYCH. 319, 328-29 (1982). 
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improvements in treatment. Advocates present the devotion of more 
money to research as a way to help patients burdened by disease. 
Meanwhile, a significant number of those same patients have trouble 
obtaining existing treatments and services that could extend and 
improve their lives because they lack adequate health insurance 
coverage.  
Patient advocates are not the only ones to blame for the 
therapeutic misconception; it has long been encouraged and 
condoned by many scientists and journalists. But advocates bear 
some of the responsibility because they occupy a special position of 
public trust and influence. Meeting their responsibilities to their 
respective constituents may require a less enthusiastic, more 
cautionary approach than is common among advocates. 
A second theme concerns the way patient advocates evaluate the 
quality of biomedical research. As one writer put it, patient advocates 
are “democratizing” biomedical science.4 This writer observed that 
advocacy can provoke thoughts “about how science might be 
different, and under what circumstances difference would mean 
improvement” in the ways science is currently practiced and 
evaluated.5 
In measuring research quality, advocates tend to focus on a 
project’s ability to benefit patients. When advocates participate in 
planning studies and setting priorities for funding, they emphasize 
how the research will affect real people. For example, advocates on a 
Department of Defense advisory committee, which evaluates 
proposals seeking funds for breast cancer research, helped establish a 
custom of starting meetings “with a moment of silence dedicated to a 
person who is living with or who has died from breast cancer.”6 
The ultimate purpose of biomedical research is to produce 
concrete health benefits, and patient advocates emphasize this aim. 
This emphasis can keep scientists focused on patients’ health needs 
and counteract competing motivations such as scientific curiosity and 
desires for career advancement.  
 
 4. Nancy Maull, Science Under Scrutiny, HARV. MAG., Mar.-Apr. 1997, at 27. 
 5. Id.  
 6. INSTITUTE OF MEDICINE, A REVIEW OF THE DEPARTMENT OF DEFENSE’S PROGRAM 
FOR BREAST CANCER RESEARCH 63 (1997). 
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However, advocates may be so intent on producing actual health 
benefits that they end up impeding the research process. For example, 
advocates may encourage Congress to set aside large portions of 
research budgets for applied studies, leaving too little for the basic 
science that underlies much clinical progress. Advocates’ quest for 
treatment improvements can also encourage excessive enthusiasm 
about novel approaches, which can end up prolonging or preventing 
the research necessary to determine the safety and effectiveness of 
those approaches. 
An example of the latter problem occurred during the 1990s, when 
some women’s health advocates fought to give women with 
advanced breast cancer liberal access to high-dose chemotherapy and 
bone marrow transplantation, a burdensome and costly procedure. 
These advocates put pressure on insurance companies to pay for the 
procedure in the absence of solid evidence that it was better than the 
standard treatment. Unwilling to take the chance of being assigned to 
the standard therapy group, many women chose not to enroll in 
randomized clinical trials comparing bone marrow transplantation 
with standard treatment. These women instead obtained the bone 
marrow transplantation procedure from physicians outside the 
research setting. As a result, it took a very long time to enroll enough 
participants to conduct the trials. When the trials were complete, the 
data showed that bone marrow transplantation was no better than 
standard treatment.7 Women would have been better off if advocates 
had been more cautious about conveying the procedure’s potential 
benefits. The advocates should have warned women that, like many 
other experimental interventions, the expensive bone marrow 
transplantation procedure might turn out to be equivalent, or even 
inferior, to existing therapies for the disease.  
The uneven quality and legitimacy of research representation is 
the third theme relevant to patient advocacy. Many advocates have a 
close personal connection to the disease group that they represent 
because they themselves have, or a close relative has, the disease. 
Some advocates become “lay experts”8 with extensive knowledge 
 
 7. See Jonas Bergh, Where Next With Stem-Cell-Supported High-Dose Therapy for 
Breast Cancer?, 355 LANCET 944 (2000). 
 8. The term is from STEVEN EPSTEIN, IMPURE SCIENCE: AIDS, ACTIVISM, AND THE 
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about the scientific and medical dimensions of the relevant health 
problem. Others rely solely on knowledge acquired through personal 
experience with illness. Some advocates receive extensive guidance 
from their constituents; others appear to take positions based 
primarily on their own assumptions about what would be best for 
patients. Some advocates receive funding from drug companies or 
other sponsors with interests that differ from those of the patients. 
Individual advocates thus vary in their abilities and qualifications to 
act as a particular group’s representative when making research 
decisions.  
Difficulties in defining the appropriate advocacy constituency 
may also affect the quality and legitimacy of research representation. 
Sometimes it is difficult for advocates to figure out which population 
to serve. For example, should advocates for disease organizations 
serve current patients, disease survivors, patients’ families, and any 
person at risk, or should they serve only some of these groups? A 
disease population can be comprised of people with diverse 
economic, social, and personal interests. An advocate’s choice of 
constituents will therefore affect the practices and policies that the 
advocate promotes.  
The above considerations are also related to fairness, which is the 
fourth advocacy theme. Advocacy is designed to ensure that the 
values and preferences of people affected by health problems are at 
the forefront of research decision-making. But in many research 
contexts, patients and other constituents have either competing or 
conflicting interests. People lacking informed and skilled advocate-
representatives may lose out when important choices about research 
are made. Unless advocates are careful, a movement that is aimed at 
increasing fairness in research decision-making could instead 
produce substantial unfairness.  
Devising a fair advocacy system requires attention to process. 
When officials and scientists consider only the views of pro-active 
advocates in their studies and policies, the interests of patients whose 
advocacy organizations lack the necessary expertise and resources to 
enter the fray are not taken into account. Thus, to promote genuine 
 
POLITICS OF KNOWLEDGE 342 (1996). 
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fairness in research decision-making, affirmative outreach and 
financial support are needed for groups that lack access and 
representation.  
The sheer number of affected groups with a stake in research 
decisions also creates a fairness issue. There are often practical limits 
on the number of constituencies that can be directly represented. For 
example, the National Institutes of Health (NIH) now has a Director’s 
Council of Public Representatives to advise on NIH programs and 
priorities and to represent the public in various agency activities.9 But 
few of the numerous patient-oriented organizations can have an 
appointed representative, as the Council is comprised of only twenty 
members. This practical constraint creates a need to devise fair 
procedures for selecting Council members and methods for obtaining 
the views of groups that are not directly represented on the Council. 
Fairness also depends on officials’ and researchers’ responses to 
patient advocacy. Fairness is not promoted when officials and 
researchers smile and appear to listen, but then ignore patient 
advocates. A fair decision-making process requires features ensuring 
that advocates’ views are taken seriously. Such features include 
required explanations of the reasons for research decisions and, in 
some situations, a chance for advocates to present arguments for 
revising those decisions.  
A fifth theme concerns the relationship of patient advocates with 
people whose academic and professional focus is bioethics. 
Advocates and bioethicists have some common goals. For example, 
both groups believe it is essential to bring the values and concerns of 
ordinary people into research ethics and policy debates. Yet there is 
discord in the relationship as well. While advocacy stresses the 
benefits attainable through research, conventional ethics put as much 
or more emphasis on the harms that can result. Ethicists are likely to 
see certain advocacy activities as disturbingly promotional, and 
advocates often see ethicists as paternalistic and overprotective.  
These differences may be part of the reason that advocates and 
bioethicists have had little to do with each other. Does this separation 
make sense? If I thought it did, I would not have written a book about 
 
 9. Notice of Establishment, 63 Fed. Reg. 63,938 (Nov. 9, 1998). 
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advocacy and research ethics. I think that the two groups could 
benefit immensely from increased interaction. With cooperation, the 
two groups could effectively promote their mutual aims and help 
each other examine the ethical implications of their work. Debates 
over conflicting views would benefit the two groups as well because 
each would come away with more reasoned positions and an 
improved understanding of their remaining disagreements. 
III. ETHICAL PRINCIPLES FOR PATIENT ADVOCACY 
Patient advocates are now influential and trusted participants in 
debates over research projects, policies, and funding priorities. 
Advocates should be aware of their ethical responsibilities in 
representing patients and lobbying for government and private 
research support. In an effort to encourage reflection on the ethics of 
patient advocacy, I offer three principles to guide patient advocates in 
research.  
First, advocates should be accurate and realistic when 
communicating with their constituents about research. Advocates 
should recognize a fiduciary responsibility to be honest about the 
uncertainties inherent in biomedical research. They should emphasize 
that scientific progress occurs slowly and incrementally, and that 
initially promising developments often fall short when subjected to 
further study. When advocates disregard this principle, patients and 
their families, as well as the broader public, are more inclined to 
entertain unfounded hope.  
Also, when advocates express undue optimism about research, 
they encourage others to give that research a disproportionate priority 
in terms of policies and funding. Research advocacy should be 
accompanied by advocacy aimed at increasing patients’ access to 
existing treatment and services that could extend and improve their 
lives. Advocates must recognize that even the most promising 
research typically offers little help to patients today. Advocates 
should promote efforts to furnish patients with the therapies, home 
care, social services, and palliative care that could confer immediate 
health benefits.  
A second ethical principle instructs advocates to consider the 
diversity of their constituents. Advocates have a tendency to promote 
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policies that favor just one segment of their constituents—well-
educated and well-insured patients, along with their families. This 
constituent group is able to take advantage of policies designed to 
increase patients’ access to clinical trials and unapproved 
interventions outside of trials, including policies requiring insurance 
coverage for patients in clinical trials and websites describing new 
trials seeking volunteers. 
But not all advocacy constituents have sufficient education and 
resources to navigate the research world on their own. For instance, 
some lack Internet access or skills. These individuals cannot take 
advantage of websites presenting information on clinical trials. 
Additionally, some constituents lack insurance coverage. These 
individuals have problems getting good standard care; insurance 
coverage for clinical trials does not benefit them.  
This diversity creates a need for advocates to communicate 
directly with constituents in different economic and educational 
situations. Consultation with a broad range of constituents will allow 
advocates to formulate decisions and policies that take into account 
the interests of all of their constituents.  
A third ethical principle holds that advocates should reject 
parochialism—the focus on a single disease or population group—in 
funding and policy work. Strong partisanship for one group is unfair 
when not everyone affected by a decision is equally represented. 
Advocates should recognize that patients and others outside of their 
usual disease constituencies have morally significant interests in 
many research decisions. Advocates should thus promote processes 
that allow broad and fair representation of disease organizations 
when policies and funding priorities are debated. Advocates should 
also make efforts to work collaboratively, rather than competitively, 
with other organizations.  
IV. FUTURE CHALLENGES FOR PATIENT ADVOCACY IN RESEARCH 
Three challenges face patient advocates in their future research 
activities. The first challenge is determining whether HIV/AIDS 
activism should continue to serve as the primary model for research 
advocacy. Certain features of HIV/AIDS advocacy are positive and 
should be emulated by other advocacy organizations. For example, 
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many HIV/AIDS advocates have acquired extensive medical and 
scientific knowledge about the disease. This strategy has increased 
HIV/AIDS advocates’ credibility and effectiveness with scientists 
and policymakers. Another positive characteristic of HIV/AIDS 
advocates is their grassroots approach to communicating with 
patients. This approach keeps advocates aware of their constituents’ 
ongoing concerns and helps advocates avoid becoming co-opted by 
the research establishment. 
Certain features of HIV/AIDS advocacy are less suited to other 
advocacy organizations, however. For example, the central aim of 
HIV/AIDS advocates has been to promote research that would lead to 
a cure for the disease. But advocates for people with conditions such 
as Parkinson’s disease and Alzheimer’s disease have constituents 
suffering from chronic, degenerative diseases that occur later in life. 
Research on these conditions is much less likely to yield a cure that 
benefits current patients than is research on HIV/AIDS, an infectious 
disease that primarily strikes young and middle-aged people.  
Another problem is that some HIV/AIDS activists have too 
eagerly embraced disease theories and treatments that lack a solid 
scientific basis. Their behavior has encouraged patients to take 
ineffective and sometimes harmful underground drugs. This 
precedent should not dissuade advocates from scrutinizing 
mainstream science. Rather, it should stand as an illustration of the 
dangers posed by wishful thinking and oversimplification in 
advocacy work. 
The second challenge for advocates is to develop adequate 
responses to the rise of industry-sponsored clinical research. 
Advocates in today’s “market economy for research”10 should alert 
patients to the possibility that industry research sponsors may offer 
financial rewards to physicians who enroll people in trials. Advocates 
should insist on adequate reviews of the ethics of research proposals 
and warn industry sponsors that they will not permit deviations from 
accepted ethical standards. Advocacy organizations should also 
formulate conflict of interest policies to govern their relationships 
with drug companies and other commercial enterprises, because 
 
 
 10. Paul T. Kefalides, Research On Humans Faces Scrutiny: New Policies Adopted, 132 
ANNALS INTERNAL MED. 513 (2000). 
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industry research sponsors are increasingly offering financial support 
to advocacy organizations that agree to help them with study 
recruitment and related activities.  
The third challenge facing patient advocates is to formulate 
positions on xenotransplantation,11 human embryonic stem cell 
research, and other novel research areas. Meeting this challenge will 
require advocates to understand new and complex scientific 
information. It will also require them to address situations in which 
patients’ interests in promoting research and advancing knowledge 
may conflict with other societal interests, such as religious and moral 
concerns about the protection of early human life, or public health 
concerns about infectious diseases that animal organ transplants 
might produce in humans. In the future, patient advocates may 
encounter previously unseen types of opposition. To continue as 
effective advocates, they will have to develop persuasive and 
responsible positions in response to this opposition. 
In writing about this topic, my goal is to help advocates, 
researchers, public officials, and bioethicists think systematically and 
creatively about how to promote ethical and effective advocate 
involvement in research decision-making. I also hope to help patients 
and the public gain an understanding of what to expect from 
biomedical research and from patient advocates, scientists, 
government officials, and science journalists. Furthermore, I hope to 
give scholars an insight into the advocacy phenomenon and build a 
foundation for future work. I consider my analysis only a first take on 
patient advocacy in research and look forward to hearing what others 
have to say about this fascinating feature of the contemporary 
research landscape. 
 
 11. Xenotransplantation is the transplantation of an organ from an individual belonging to 
one species into the body of an individual belonging to a different species. The goal of this 
research is to extend the lives of humans through transplantation of non-human hearts, kidneys, 
livers, and other vital organs. See INSTITUTE OF MEDICINE, XENOTRANSPLANTATION: SCIENCE, 
ETHICS, AND PUBLIC POLICY (1996).  
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